Studies analyzed differential transcriptional expression between bevacizumab-resistant GBM patients and bevacizumab-naïve patients and suggested that macrophage migration inhibitory factor (MIF) was significantly downregulated and correlated with increased M2-like macrophages localizing to the tumor edge and tumor growth. The gene discussed is MIF; the disease is glioblastoma.